329 studies found for:    "Thyroid Neoplasms"
Show Display Options
Download search resultsDownload the search results for:
"Thyroid Neoplasms" (329 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed
Has Results
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
Conditions: Insular Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage II Follicular Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Papillary Thyroid Cancer
Intervention: Drug: Bortezomib
2 Active, not recruiting Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Conditions: Recurrent Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
Interventions: Drug: decitabine;   Radiation: iodine I 131;   Biological: recombinant thyrotropin alfa;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography
3 Active, not recruiting Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
Conditions: Recurrent Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: sunitinib malate;   Other: laboratory biomarker analysis
4 Active, not recruiting Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
Conditions: Recurrent Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: sunitinib malate;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Active, not recruiting AZD6244 in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
Conditions: Recurrent Thyroid Cancer;   Stage I Papillary Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IV Papillary Thyroid Cancer
Interventions: Drug: selumetinib;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Active, not recruiting Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
Conditions: Anaplastic Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis
7 Recruiting Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Conditions: Recurrent Thyroid Cancer;   Stage I Follicular Thyroid Cancer;   Stage I Papillary Thyroid Cancer;   Stage II Follicular Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
Interventions: Drug: cediranib maleate;   Drug: lenalidomide;   Other: laboratory biomarker analysis
8 Recruiting Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Conditions: Insular Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage I Follicular Thyroid Cancer;   Stage I Papillary Thyroid Cancer;   Stage II Follicular Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
Interventions: Drug: cabozantinib-s-malate;   Other: laboratory biomarker analysis
9 Terminated Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
Conditions: Anaplastic Thyroid Cancer;   Insular Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Papillary Thyroid Cancer
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
10 Recruiting Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
Conditions: Follicular Thyroid Cancer;   Insular Thyroid Cancer;   Papillary Thyroid Cancer;   Recurrent Thyroid Cancer
Interventions: Drug: dabrafenib;   Drug: trametinib;   Other: Correlative Studies
11 Not yet recruiting Trametinib and Radioiodine in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
Conditions: Recurrent Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
Interventions: Radiation: iodine I 124;   Drug: trametinib;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: positron emission tomography;   Radiation: iodine I 131;   Procedure: computed tomography
12 Completed Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
Conditions: Insular Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage II Follicular Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Papillary Thyroid Cancer;   Thyroid Gland Medullary Carcinoma
Intervention: Drug: vorinostat
13 Active, not recruiting Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
Conditions: Recurrent Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
Interventions: Drug: pazopanib hydrochloride;   Radiation: iodine I 131
14 Completed Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
Conditions: Metastatic Differentiated Thyroid Cancer;   Metastatic Poorly Differentiated Thyroid Cancer;   Metastatic Anaplastic Thyroid Cancer;   Metastatic Medullary Thyroid Cancer
Intervention: Drug: sorafenib
15 Recruiting Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia
Conditions: Thyroid Neoplasms;   Thyroid Cancer
Intervention: Procedure: Histological investigation of the SN
16 Not yet recruiting Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer
Conditions: Recurrent Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer
Interventions: Drug: sorafenib;   Drug: everolimus
17 Active, not recruiting Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
Conditions: Recurrent Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Papillary Thyroid Cancer
Interventions: Biological: ziv-aflibercept;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Other: pharmacological study;   Other: laboratory biomarker analysis
18 Completed Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm
Conditions: Cancer of the Thyroid;   Neoplasms, Thyroid;   Thyroid Adenoma;   Thyroid Cancer;   Thyroid Carcinoma
Intervention:
19 Recruiting Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Conditions: Papillary Thyroid Cancer;   Follicular Thyroid Cancer;   Differentiated Thyroid Cancer
Intervention: Drug: SU011248, Sutent
20 Recruiting Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study
Conditions: Papillary Carcinoma of Thyroid Metastatic to Regional Lymph Node;   Metastatic Medullary Thyroid Cancer;   Follicular Thyroid Cancer Lymph Node Metastasis
Interventions: Drug: Ferumoxytol;   Device: lymphotrophic superparamagnetic nanoparticles (LSN MRI).

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years